Prophylaxis of COVID-19 Disease With Ivermectin in COVID-19 Contact Persons [German: Prophylaxe Der COVID-19-Erkrankung Mit Ivermectin Bei COVID-19 Kontaktpersonen]

Placebo-controlled Randomized Double-blind Phase III Study on the Efficacy and Safety of Ivermectin Tablets (Driponin®) for the Prophylaxis of COVID-19 Disease in Adult Contact Persons Living in the Household of a Person Suffering From COVID-19 [German: Placebo-kontrollierte Randomisierte Doppel-blinde Phase III Studie Zur Wirksamkeit Und Sicherheit Von Ivermectin Tabletten (Driponin®) für Die Prophylaxe Der COVID-19 Erkrankung Bei im Haushalt Lebenden Erwachsenen Kontaktpersonen Einer an COVID-19 Erkrankten Person]

The Prevent-COVID study is a prospective, multicenter, randomized, two-armed, placebo-controlled, double-blind, interventional study in which the efficacy and safety of ivermectin in COVID-19 post-exposure prophylaxis (PEP) is examined in adult, close family contacts living in the household of a subject suffering from COVID-19.

Study Overview

• Status: Not yet recruiting
• Conditions: Covid19
• Intervention / Treatment: Drug: Ivermectin; Drug: Placebo

Detailed Description

Study population and study sites:

The study is carried out in about 30 private practices or clinics in Germany that regularly carry out SARS-CoV-2 PCR tests and treat COVID-19 patients.

Adult close contact persons of newly diagnosed COVID-19 patients living in the same household are considered for participation.

Study duration and assessment:

The study will last 14 days, in which the following study-specific measures will be undertaken:

• Documentation of demographics (age, gender, ethnicity, height and weight, degree of relationship to the COVID-19 patient)
• Documentation of current comorbidities
• Documentation of current medical accompanying measures
• Documentation of the general condition
• Vital signs
• COVID-19 symptoms
• SARS-CoV-2 PCR test: Only for medical confirmation of the presence of COVID-19 symptoms during an unplanned COVID-19 visit or final visit.
• Subject diary (daily measurement of body temperature, contact intensity with the index person)
• Pregnancy test in women of childbearing potential

Objectives:

Primary Objective: To demonstrate the efficacy of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person)

Secondary objectives:

• To demonstrate the safety of ivermectin in the COVID-19 post-exposure prophylaxis of adult contact persons living in the household of a person suffering from COVID-19 (index person)
• To determine the severity of the symptoms of subjects suffering from COVID-19 during the study period and the comparison between the ivermectin and the placebo group.

IMP: Driponin® is an approved drug with the active ingredient Ivermectin, used to treat parasitic infections. One tablet Driponin® contains 3 mg Ivermectin. As part of the clinical trial, the medicinal product will be examined with regard to indication, dosage and application schedule deviating from the intended purpose and the package insert.

• Study Type: Interventional
• Enrollment (Anticipated): 412
• Phase: Phase 3

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 16 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• age of at least 18 years
• adult subject living in the same household as a related COVID-19 patient (index person)

Exclusion Criteria:

• index person has COVID-19 symptoms for more than 5 days at enrolment
• known past COVID-19 or current infection confirmed by positive SARS-CoV-2 PCR test at enrolment
• symptoms at enrolment indicating COVID-19: increased body temperature OR acute respiratory symptoms of any severity OR newly occuring loss of taste or smell OR ague OR sumulatneously occuring headache and body ache
• known contraindications to the use of the study medication (in alignemnt with current summary of product characteristics of Driponin®)
• known chronic obstructive pulmonary disease
• known acute or chronic hepatitis B or C or other clinically recognizable or known liver dysfunction
• known HIV infection or AIDS
• known symptomatic allergic rhinitis
• current (inlcuding up to 24 hours before enrolment) or planned (during next 14 days) therapy with non-steroidal anti-inflammatory drugs, other pain medication (e.g., ASS (including prophylactic use), metamizol)
• recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic steroids
• recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with systemic immunosuppressive drugs
• known or clinically suspected disturbance of the blood-brain-barrier (e.g., ABCB-1 (=MDR1) mutation) as well as history of neurotoxic effects by ivermectin or other substrates/inhibitors of the para-glycoprotein (P-gp)
• known hypersensitivity/intolerance to the study drug or any of its exicpients, in particular ivermectin, microcrystalline cellulose, pre-agglutinated starch, butyl hydroxyanisole or magnesium stearate
• pregnancy or lactation
• women of child-bearing potential planning to become pregnant or not using effective mehods of contraception
• any other severe disorder, which in the opinion of the investigator would preclude the subject from trial participation
• previous or planned (during next 14 days) vaccination with any COVID-19 vaccine
• recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with Ivermectin
• recent (up to 28 days before enrolment) or planned (during next 14 days) therapy with drugs with evident or potential benefit in treating COVID-19 in alignemnt with RKI
• apparent unreliability or lack of compliance (e.g., not willing to orally administer the required number of tablets on 2 days or not willing to complete the subject diary during 14 days)
• known alcohol or drug abuse
• participation in another clinical trial during the last 30 days or planned participation in another clinical trial during the next 30 days
• previous participation in this same clinical trial

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: Double

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ivermectin; 2 doses of ivermectin at day 0 and day 2	Drug: Ivermectin; 2 doses of Ivermectin will be administered with 48 hours time interval. The dosage is based on body weight calculated as follows: 15 mg for 40-60 kg = 5 tablets à 3 mg; 18 mg for 60-80 kg = 6 tablets à 3 mg; 24 mg for > 80 kg = 8 tablets à 3 mg each This corresponds to an ivermectin dose of about 300 µg / kg.; Other Names: Driponin; ATC-code P02CF01; Substance code SUB12089MIG
Placebo Comparator: Placebo; 2 doses of placebo at day 0 and day 2	Drug: Placebo; An analogous number of tablets is administered for placebo: 5 tablets for 40-60 kg; 6 tablets for 60-80 kg; 8 tablets for > 80 kg The size, appearance, smell and taste of the tablets of placebo are identical to Ivermectin.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
COVID-19 disease	Occurrence of a COVID-19 disease up to the final visit (day 14), defined as the presence of the clinical condition according to the RKI case definition (acute respiratory symptoms of any severity OR new loss of smell and taste occurred OR illness-related death) AND a positive SARS-CoV-2 PCR test on the day the symptoms were determined (+/- 4 days)	Day 14

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Adverse events and side effects	Number and severity of adverse events and side effects.	14 days
Type, number and severity of symptoms	Type, number and severity of symptoms within the 14-day of study on subjects suffering from COVID-19 (incl. hospitalization, oxygen saturation and demand, intensive care treatment)	14 days
Severity of the COVID-19 disease	Severity of the COVID-19 disease according to the investigator's assessment	14 days

Collaborators and Investigators

• Sponsor: Infectopharm Arzneimittel GmbH
• Collaborators: GKM Gesellschaft für Therapieforschung mbH

Study record dates

Study Major Dates

• Study Start (Anticipated): November 1, 2021
• Primary Completion (Anticipated): March 1, 2022
• Study Completion (Anticipated): March 1, 2022

Study Registration Dates

• First Submitted: September 28, 2021
• First Submitted That Met QC Criteria: September 28, 2021
• First Posted (Actual): September 29, 2021

Study Record Updates

• Last Update Posted (Actual): November 2, 2021
• Last Update Submitted That Met QC Criteria: November 1, 2021
• Last Verified: November 1, 2021

More Information

Terms related to this study

• Keywords: COVID-19 post-exposure prophylaxis
• Additional Relevant MeSH Terms: Coronavirus Infections; Coronaviridae Infections; Nidovirales Infections; RNA Virus Infections; Virus Diseases; Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Pneumonia, Viral; Pneumonia; Lung Diseases; COVID-19; Anti-Infective Agents; Antiparasitic Agents; Ivermectin
• Other Study ID Numbers: PREVENT-COVID; 2021-002445-15 (EudraCT Number)

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No